Chronic Pain

This report summarises what Blossom’s database shows about psychedelic and dissociative compounds for chronic pain, and what it does not show. The short version: this is a field where one compound, ketamine, has genuine but limited and short-lived analgesic evidence, while the classic psychedelics and MDMA remain at the pilot, case-report and healthy-volunteer stage. The most important honest point is that much of what looks like pain relief may be relief of the depression and distress that accompany chronic pain, which is clinically valuable but not the same as treating the pain itself.

A note before the evidence

This page is a research summary, not medical advice, and nothing here is a treatment recommendation. Of the compounds discussed, only ketamine is in routine (specialist, off-label) clinical use for pain; the classic psychedelics are investigational and not approved for chronic pain anywhere. Chronic pain is treatable through established multimodal care, and decisions about that care belong with a qualified clinician. Self-treating chronic pain with unregulated psychedelics is neither safe nor evidence-based.

A word on the numbers. Blossom tracks 174 papers and 78 trials tagged to this topic, and those counts appear on this page. The tag is unusually leaky here: most of those papers are about depression, PTSD, headache disorders, drug mechanism, or experiments in healthy volunteers, and are tagged because pain is mentioned or shares a mechanism. The genuinely chronic-pain-specific clinical core is small, on the order of a dozen patient studies, and most of those are pilots, case reports or surveys. Read the counts as breadth of coverage, not as a deep chronic-pain evidence base.

What we mean by chronic pain

Chronic pain is pain lasting beyond about three months, and it spans very different mechanisms: neuropathic pain from nerve damage, nociplastic pain such as fibromyalgia where the pain system itself is sensitised, and persistent pain from cancer, arthritis or injury. It is common and disabling, affecting roughly a fifth of adults worldwide and ranking among the top causes of disability[1]The Lancet, chronic pain seminar (2021). It is also deeply entangled with mental health: depression, anxiety and poor sleep both worsen pain and are worsened by it. That entanglement matters for everything below, because a treatment that lifts mood and changes how the brain weights pain can look like analgesia without directly blocking pain signals.

Ketamine: real evidence, real limits

Ketamine is the compound to take seriously here. A dissociative anaesthetic that blocks the NMDA receptor, it is thought to interrupt the central sensitisation underlying much chronic pain, and unlike the classic psychedelics it is already used, off-label, in specialist pain clinics. But its evidence is carefully bounded. The 2018 consensus guidelines from the main anaesthesia and pain-medicine societies graded it moderate for complex regional pain syndrome (with relief up to 12 weeks) and weak or no evidence for neuropathic pain, fibromyalgia, cancer pain, headache and spinal pain[2]ASRA/AAPM/ASA consensus guidelines (2018), noting that most underlying studies were small and poorly blinded.

The defining weakness is durability. In the cleanest fibromyalgia trial, a randomised active-placebo study, a short S-ketamine infusion cut pain acutely but the effect had disappeared within a week, tracking the drug’s presence in the blood[3]European J. Pain, S-ketamine fibromyalgia (2012); a refractory chronic-migraine pilot likewise saw pain fall during treatment then return to baseline by six weeks[4]J. Clinical Pharmacology, ketamine migraine (2021). Oral ketamine may decline more slowly, but a systematic review found only five studies of low quality and non-standardised dosing[5]J. Pain Research, oral ketamine review (2026). Some clinics now pair ketamine infusions with psychotherapy to try to extend the benefit, with small pilots reporting improved pain and mood[6]Frontiers in Pain Research, ketamine + therapy (2023), but the core problem stands: durable relief requires repeated dosing, and repeated ketamine carries genuine risks of dependence and bladder damage.

Psilocybin and the classic psychedelics: early and uncontrolled

For psilocybin, the honest summary is that the chronic-pain evidence barely exists yet. The most substantial study is an open-label fibromyalgia pilot of just five people that reported very large reductions in pain severity at one month, but had no comparison group and stopped recruiting early[7]Frontiers in Pain Research, psilocybin fibromyalgia (2025). The rest is anecdote: a three-person case series of microdosing for neuropathic pain[8]PAIN, psilocybin microdose case series (2022) and a single phantom-limb case combining psilocybin with mirror therapy[9]Neurocase, psilocybin phantom-limb (2018). Online surveys of chronic-pain users report that larger doses ease pain more than conventional medicines[10]British J. Pain, chronic-pain user survey (2022), but self-report surveys cannot establish that a treatment works and are wide open to bias.

The recurring shape of this evidence is large effects from tiny, uncontrolled samples. A Cohen’s d around minus two sounds dramatic, but from five open-label patients with a confidence interval spanning almost the whole plausible range, it is a hypothesis, not a finding. No randomised controlled trial of a classic psychedelic for chronic pain has reported yet. Several are now running, and they, not the current pilots, will tell us whether there is a real effect.

LSD: a healthy-volunteer signal that did not replicate

LSD is often cited in this context, but its evidence is experimental pain in healthy volunteers rather than treatment of patients. The key study found that a 20 microgram dose increased how long healthy volunteers could tolerate cold-pressor pain and reduced its unpleasantness, at a sub-perceptual dose[11]J. Psychopharmacology, low-dose LSD (2020). That is a genuine, carefully measured effect, and it fits older uncontrolled reports of LSD analgesia in dying patients.

It should be read alongside its own replication. A 2025 placebo-controlled study at 15 micrograms found no analgesic effect across the sample[12]British J. Pain, LSD 15 ug replication (2025), with only a faint first-dose signal in a post-hoc subgroup, suggesting the effect is dose-sensitive and fragile. Even taken at face value, tolerating cold water for a few extra seconds is a long way from relieving established neuropathic or nociplastic pain. The most defensible reading is that low-dose LSD can nudge acute pain perception in the lab, which is mechanistically interesting and clinically unproven.

MDMA: almost nothing direct

MDMA belongs on this page mainly to be honest about how little there is. The only chronic-pain data is an exploratory sub-analysis of 32 people in an open-label MDMA-for-PTSD study, where pain intensity and disability fell, reaching significance only in the most severely affected subgroup[13]Frontiers in Psychiatry, MDMA + PTSD pain (2022). Because the parent trial was treating PTSD, the most likely explanation is that easing trauma eased the pain bound up with it, a real and useful effect, but not evidence that MDMA is an analgesic. No dedicated MDMA chronic-pain trial has reported.

How might these work, and what are they really treating?

The proposed mechanisms are plausible but remain hypotheses. For the classic psychedelics, the leading ideas are that 5-HT2A activation could "reset" the altered brain connectivity of chronic pain, promote neuroplasticity, and dampen central sensitisation and inflammation[14]Reg. Anesthesia & Pain Medicine review (2020). For ketamine, NMDA blockade and enhanced descending inhibition are better established. But the cleanest thread running through the data is different: the effects seem to land most reliably on pain’s emotional and cognitive dimension, its unpleasantness, the catastrophising, the depression woven through it, rather than on the raw nociceptive signal.

This is the central interpretive point of the whole page. Chronic pain is partly a disorder of how the brain processes and suffers pain, and treatments that act on mood, meaning and plasticity might genuinely reduce suffering without being painkillers in the conventional sense. That would be clinically valuable. But it is a different claim from "psychedelics relieve pain", and conflating the two is exactly the kind of overstatement an honest reading has to resist. Tellingly, one ketamine trial tagged to chronic pain actually measured depression as its outcome, not pain.

Safety, durability and the dosing problem

Across the field, two practical issues shadow the science. The first is durability: ketamine’s benefit fades with the drug, and even the classic psychedelics, sold on the promise of lasting change, have not shown durable pain relief in controlled conditions. The second is that durable relief by repeated dosing brings its own harms, ketamine in particular carries dependence potential and a well-documented risk of bladder toxicity with frequent use. Supervised, occasional dosing in a trial is not the same as the chronic dosing that real pain management would demand, and the safety profile of one says little about the other.

There is also the blinding problem. Both ketamine and the psychedelics produce unmistakable acute effects, so patients usually know what they received, which inflates apparent benefit. That a new trial resorts to propofol sedation simply to hide ketamine’s dissociation shows how seriously the field now takes this. Until trials solve blinding and follow patients long enough to test durability, the encouraging early numbers should be held loosely.

Reading this honestly

So where does chronic pain sit? It is one of the more sobering topics in psychedelic medicine. The compound with real evidence, ketamine, is not a classic psychedelic, works only in some conditions, and does not last. The classic psychedelics and MDMA are at the stage of small pilots, single cases, surveys and healthy-volunteer experiments, with the one clean LSD signal failing to replicate. The most credible interpretation is that these compounds may help with the emotional and central-nervous-system dimension of chronic pain, the suffering and the depression, more than with nociception itself, which is worth taking seriously and worth testing properly. For now, the honest position is plain: this is a promising, unproven area where the hype runs well ahead of the evidence, and the controlled trials that would settle it are only just beginning.